Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2002-09-13
2009-06-16
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C514S557000, C514S171000, C514S034000
Reexamination Certificate
active
07547673
ABSTRACT:
The present invention relates to methods of treating a cancerous tumor using selective inhibitors of ATP production. The present invention also relates to pharmaceutical preparations comprising such inhibitors and methods for administering them intraarterially directly to a tumor, as well as methods for identifying compositions that selectively inhibitor ATP production for use in the invention.
REFERENCES:
patent: 4536387 (1985-08-01), Sakamoto et al.
patent: 5759547 (1998-06-01), Maione
patent: 5759837 (1998-06-01), Kuhajda et al.
patent: 5854067 (1998-12-01), Newgard et al.
patent: 6284786 (2001-09-01), Casciari et al.
patent: 6312662 (2001-11-01), Erion et al.
patent: 6448030 (2002-09-01), Rust et al.
patent: 6670330 (2003-12-01), Lampidis et al.
patent: 2001/0046997 (2001-11-01), Abraham et al.
patent: 2002/0006915 (2002-01-01), Mack Strong et al.
patent: 2002/0068711 (2002-06-01), Pedersen et al.
patent: 2003/0018166 (2003-01-01), Sacchettini et al.
patent: 2003/0139331 (2003-07-01), Martin et al.
patent: 2004/0029826 (2004-02-01), Sokoloff et al.
patent: 2004/0167079 (2004-08-01), Tidmarsh
patent: 2004/0167196 (2004-08-01), Tidmarsh
patent: 2006/0154867 (2006-07-01), Sokoloff et al.
Fiebig et al., “Relevance of Tumor Models for Anticancer Drug Development”, Contrib. Oncol. Basel. Karger, vol. 54, pp. 109-120 (1999).
Chemical Abstracts 124:193528, “Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil”, Kerr et al (1995).
Kerr et al., “Phase I Clinical and Pharmacokinetic Study of Leucovorin and Infusional Hepatic Arterial Fluorouracil”, Journal of Clinical Oncology, vol. 13, No. 12, pp. 2968-2972 (Dec. 1995).
Lin et al, Effects of 90Y-Microspheres on Liver Tumors: Comparison of Intratumoral Injection Method and Intra-Arterial Injection Method, Nov. 2000, The Journal of Nuclear Medicine, vol. 41, No. 11, p. 1892.
Kerr et al, Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial flurouracil, Dec. 1995, Journal of Clinical Oncology, vol. 13, No. 12, p. 2968.
Arafat et al.; “Toxicities Related to Intraarterial Infusion of Cisplatin and Etoposide in Patients with Brain Tumors”, Journal of Neuro-oncology 42: 73-77, (1999).
Bar et al.; “Sorbitol Removal by the Metastatic Liver: A Predictor of Systemic Toxicity of Intra-arterial Chemotherapy in Patients with Liver Metastases”, Journal of Hepatology 30: 1112-1118, (1999).
Geschwind et al.; “Novel Therapy for Liver Cancer: Direct Intraarterial Injection of a Potent Inhibitor of ATP Production”, Cancer Research, 62:3909-3913, (2002).
Gobin et al.; “Intraarterial Chemotherapy for Brain Tumors by Using a Spatial Dose Fractionation Algorithm and Pulsatile Delivery”, Radiology 218(3): 724-732, (Mar. 2001).
Ko et al., “Metabolic Properties of the Rabbit VX2 Tumor Model Following Liver Implantation: Role for Hexokinase”, Cancer Research 42: 519(#2796), (Mar. 2001).
Ko et al.; “Glucocatabolism in the Rabbit VX2 Tumor Model for Liver Cancer: Characterization and Targeting Hexokinase”, Cancer Letters 173: 83-91, (2001).
Kostron et al.; “Photodynamic Treatment of Malignant Brain Tumors”, Jg 102, Heft 18 : 531-535, (Sep. 28, 1990).
Mathupala et al.; “Glucose Catabolism in Cancer Cells”, The Journal of Biological Chemistry, 276(46): 43407-43412, (Nov. 16, 2001).
Pedersen et al.; “Mitochondrial Bound Type II Hexokinase: a Key Player in the Growth and Survival of Many Cancers and an Ideal Prospect for Therapeutic Intervention”, Biochimica and Biophysica Acta 1555: 14-20, (2002).
Soulen et al.; “Intraarterial Chemotherapy with Limb-sparing Resection of Large Soft-tissue Sarcomas of the Extremities”, JVIR, 3: 659-663, (1992).
Wang et al.; “Isolated Lower Extremity Chemotherapeutic Infusion for Treatment of Osteosarcoma: Experimental Study and Preliminary Clinical Report”, J. Vasc. Interv. Radiol. 12: 731-737, (2001).
Johns Hopkins Medical Institutions Office of Communications and Public Affairs “Energy Blocker May Be Potential Liver Cancer treatment”, www.hopkinsmedicine.org/press/2002/July/020715.htm.
Pederson, P., ““Energy Blocker” Kills Big Tumors in Rats”, Audio File—Johns Hopkins Medicine, Office of Corporate Communications, Oct. 14, 2004.
Ko et al., “Advanced Cancers: Eradication in All Cases Using 3-bromopyruvate Therapy to Deplete ATP⋆, ⋆⋆”, Press Release, Nov. 5, 2004.
Ko et al., “Advanced Cancers: Eradication in All Cases Using 3-bromopyruvate Therapy to Deplete ATP⋆, ⋆⋆”, BBRC, 324(1):269-275, (2004).
Geschwind Jean-Francois H.
Ko Young He
Pedersen Peter L.
Foley & Hoag LLP
Marschel Ardin
Russell, Esq. Hathaway P.
The Johns Hopkins University
Vakili Zohreh
LandOfFree
Therapeutics for cancer using 3-bromopyruvate and other... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutics for cancer using 3-bromopyruvate and other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutics for cancer using 3-bromopyruvate and other... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4060018